RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:586

Cystic fibrosis

medium confidenceDisorder

Also known as: CF · Mucoviscidosis

Publications

165,789

99.7th percentile

Trials

1,161

Interventional, condition-specific

Researchers

1,333

Distinct authors in sample

Gene link

CFTR

Definitive

Readiness

6/6

Stages with a signal

Clinical definition (Orphanet)

A rare, genetic pulmonary disorder characterized by sweat, thick mucus secretions causing multisystem disease, chronic infections of the lungs, bulky diarrhea and short stature.

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

cystic fibrosis · cystic fibrosis lung disease, modifier of · mucoviscidosis · pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

6/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — CFTR

  2. LiteraturePresent

    165,789 matched papers (80,928 in last 10 years) Source

  3. Phenotype characterisedPresent

    84 HPO annotations (e.g. Hypospadias; Nephrotic syndrome; Macrotia) Source

  4. Animal modelPresent

    31 genotype models (Mus musculus, Rattus norvegicus, Danio rerio) Source

  5. Orphan designationPresent

    15 FDA · 5 EMA designations (15 FDA orphan-indication approvals) — e.g. colistimethate sodium Source

  6. Interventional trialPresent

    1,161 matched on ClinicalTrials.gov (102 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CFTR).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

84

Associated phenotypes · MONDO:0009061

  • Hypospadias
  • Nephrotic syndrome
  • Macrotia
  • Wide nasal bridge
  • Megaloblastic anemia

Showing 5 of 84 — open Monarch for the full list.

Animal models (Monarch / Alliance)

31

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

30

Designations · 15 with FDA orphan-indication approval

  • FDA colistimethate sodiumCystic Fibrosis respiratory infection · 2020-03-19 · Not FDA Approved for Orphan Indication
  • FDA sodium fusidateCystic Fibrosis · 2020-02-13 · Not FDA Approved for Orphan Indication
  • FDA heparin sodiumCystic Fibrosis · 2019-07-29 · Not FDA Approved for Orphan Indication
  • FDA gallium citrateCystic Fibrosis · 2019-06-24 · Not FDA Approved for Orphan Indication
  • FDA ascorbic acidCystic Fibrosis · 2018-07-30 · Not FDA Approved for Orphan Indication
  • FDA teicoplaninCystic Fibrosis Staphylococcus aureus Infections · 2018-05-24 · Not FDA Approved for Orphan Indication
  • FDA BrevenalCystic Fibrosis · 2018-04-02 · Not FDA Approved for Orphan Indication
  • FDA N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamideCystic Fibrosis · 2018-03-07 · Not FDA Approved for Orphan Indication

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

154

Drugs / clinical candidates · MONDO_0009061

CTD chemicals (MyDisease.info)

31 associated chemicals · 143 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • 5-O-(5-amino-5-deoxyribofuranosyl)-1N-(4-amino-2-hydroxybutanoyl)paromamine · therapeutic
  • Acetylcysteine · therapeutic
  • Amikacin · therapeutic
  • Aminoglycosides · therapeutic
  • Anti-Bacterial Agents · therapeutic
  • Aztreonam · therapeutic
  • Ciprofloxacin · therapeutic
  • Colistin · therapeutic
  • Deamino Arginine Vasopressin · therapeutic
  • denufosol tetrasodium · therapeutic
  • Docosahexaenoic Acids · therapeutic
  • Fosfomycin · therapeutic

Pathways: ABC transporters; MAPK signaling pathway; cAMP signaling pathway; Cytokine-cytokine receptor interaction; NF-kappa B signaling pathway; FoxO signaling pathway; Sphingolipid signaling pathway; Cell cycle

MyDisease.info · MONDO:0009061

Literature

Is anyone studying this?

165,789

165,789 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

165,789 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

80,928 in the last 10 years · medium confidence · 99.7th percentile (publications denominator)

Phrase hits: 159,087 · MeSH hits: 5,490

Open Europe PMC search

Who's working on it?

1,333

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Abrami M4 papers · 2026

    Department of Engineering and Architecture, Trieste University, via Valerio 6, I-34127 Trieste, Italy.

    Papers in Europe PMC
  2. 02
    Grassi G4 papers · 2026

    Clinical Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, Strada di Fiume 447, I-34149 Trieste, Italy.

    Papers in Europe PMC
  3. 03
    Grassi M4 papers · 2026

    Department of Engineering and Architecture, Trieste University, via Valerio 6, I-34127 Trieste, Italy. Electronic address: mario.grassi@dia.units.it.

    Papers in Europe PMC
  4. 04
    Birket SE3 papers · 2026

    Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

    Papers in Europe PMC
  5. 05
    Johnson PN3 papers · 2026

    Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, The University of Oklahoma, Oklahoma City, OK, USA.

    Papers in Europe PMC
  6. 06
    Liu X3 papers · 2026

    Department of Pulmonary and Critical Care Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

    Papers in Europe PMC
  7. 07
    Miller JL3 papers · 2026

    Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, The University of Oklahoma, Oklahoma City, OK, USA.

    Papers in Europe PMC
  8. 08
    Visentin S3 papers · 2026

    Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Torino, Italy.

    Papers in Europe PMC
  9. 09
    Wang J3 papers · 2026

    School of Physical Education and Sport Science, Fujian Normal University, Fuzhou 350117, China.

    Papers in Europe PMC
  10. 10
    Abou Alaiwa MH2 papers · 2026

    Department of Internal Medicine, Roy J and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1,161

interventional trials for this specific condition

1,161 interventional trials matched this specific condition name; 102 currently recruiting in our sample.

Data as of 11 September 2026 · last trial check 28 July 2026

1,161 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.9th percentile).

medium confidence · 99.9th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1,161 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

509 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 79 · after dedupe 76 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 76 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (76)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Cystic fibrosis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

Directly listed under NPRD Group 2.

Group 2 — long-term / lifelong lower-cost interventions

NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.

Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
  • Maulana Azad Medical College — New Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
  • King Edward Memorial Hospital — Mumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
  • Assam Medical College & Hospital — Dibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Cystic fibrosis" OR "Mucoviscidosis" OR "cystic fibrosis lung disease, modifier of" OR "pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis") OR (MESH:"Cystic Fibrosis") OR ("CFTR" OR "CFTR syndrome" OR "CFTR-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Cystic Fibrosis

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cystic fibrosis" OR "Mucoviscidosis" OR "cystic fibrosis lung disease, modifier of" OR "pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis"

Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1161 interventional · 509 observational · 7 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: CF

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T14:27:49.588Z